Furthermore, in an in-vitro model of triple-negative breast cancer, TDO2 inhibition by 680C91 significantly reduced intracellular KYN levels, leading to their increased sensitivity to the process of programmed cell death, as well as reduced their ability to proliferate, migrate and invade (Table 1) [71]. Here, TDO2 is linked to triple-negative breast carcinoma.